Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Change in Cash (2020 - 2025)

Historic Change in Cash for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to -$366000.0.

  • Treace Medical Concepts' Change in Cash rose 9397.13% to -$366000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year decrease of 19155.63%. This contributed to the annual value of -$1.6 million for FY2024, which is 7485.75% up from last year.
  • Latest data reveals that Treace Medical Concepts reported Change in Cash of -$366000.0 as of Q3 2025, which was up 9397.13% from -$5.3 million recorded in Q2 2025.
  • Treace Medical Concepts' 5-year Change in Cash high stood at $103.4 million for Q2 2021, and its period low was -$69.1 million during Q4 2022.
  • Over the past 5 years, Treace Medical Concepts' median Change in Cash value was -$3.6 million (recorded in 2021), while the average stood at -$547000.0.
  • As far as peak fluctuations go, Treace Medical Concepts' Change in Cash skyrocketed by 3479899.33% in 2021, and later crashed by 180493.66% in 2022.
  • Over the past 5 years, Treace Medical Concepts' Change in Cash (Quarter) stood at -$3.6 million in 2021, then plummeted by 1804.94% to -$69.1 million in 2022, then skyrocketed by 108.26% to $5.7 million in 2023, then plummeted by 113.32% to -$760000.0 in 2024, then surged by 51.84% to -$366000.0 in 2025.
  • Its Change in Cash was -$366000.0 in Q3 2025, compared to -$5.3 million in Q2 2025 and $2.0 million in Q1 2025.